AI-generated summary
The authors compared 29 patients given high-dose neoadjuvant chemoradiotherapy plus endoscopic Nd:YAG laser tumor debulking with 31 historical patients given chemoradiotherapy alone for locally advanced esophageal cancer. The laser-treated group had longer reported survival (30.1 versus 16.5 months) and more relief of dysphagia, with three laser-related complications. The authors call for longer follow-up and a prospective comparative trial.
- Who or what was studied
- Patients with advanced locoregional esophageal carcinoma: 29 in a prospective laser group and 31 in a retrospective reference group
- Limits stated in the abstract
- The comparison group was retrospective and historical, the study was small, and the authors state that longer follow-up and a prospective comparative trial are needed.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Total energy
- 443 J
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Laser, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.